Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis

Devlikamova F.I.

Kazan State Medical Academy — branch of Russian medical Academy of continuing professional education

ORCID: 0000-0003-4411-7051

Safina D.R.

Kazan Federal University

ORCID: 0000-0002-6466-4979

Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis

Authors:

Devlikamova F.I., Safina D.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2): 69‑79

DOI: 10.17116/jnevro202512502169

Downloaded: 4

Contact the author

Table of contents

To cite this article:

Devlikamova FI, Safina DR. Efficacy and safety of fonturacetam in asthenia: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2):69‑79. (In Russ.)
https://doi.org/10.17116/jnevro202512502169

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)

Close metadata

OBJECTIVE

To determine the efficacy and safety of Actitropil (fonturacetam) in asthenia.

MATERIAL AND METHODS

This meta-analysis includes the studies results on fonturacetam efficacy in asthenia. After checking for the risk of bias and the risk of systematic errors, the meta-analysis included 11 articles. The efficacy and safety of fonturacetam at a daily dose of 200 mg was assessed, since patients received this dose in all included studies.

RESULTS

The meta-analysis included 549 patients (mean age 45.9 years, 95% CI: 38.1—53.7). In all studies, the level of asthenia according to the MFI-20 scale was significantly reduced after a course of fonturacetam (one month course, assessment on the thirtieth day from the beginning of treatment), by an average of 16.3 points (95% CI: 8.85—23.85 points) (p<0.0001). Additional effects of fonturacetam: positive effect on emotional background, sleep, cognitive functions, quality of life. High patient satisfaction with treatment was observed. During treatment with fonturacetam, the frequency of side effects averaged 5.5%. Side effects were transient and completely regressed within a week of continued treatment.

CONCLUSION

Fonturacetam effectively reduces the level of asthenic syndrome after a month of therapy.

Keywords:

fonturacetam

Actitropil

asthenic syndrome

chronic fatigue syndrome

effectiveness

safety

Authors:

Devlikamova F.I.

Kazan State Medical Academy — branch of Russian medical Academy of continuing professional education

ORCID: 0000-0003-4411-7051

Safina D.R.

Kazan Federal University

ORCID: 0000-0002-6466-4979

Received:

20.01.2025

Accepted:

27.01.2025

List of references:

Akhapkina VI, Fedin AI, Avedisova AS, Akhapkin RV. Effektivnost’ fenotropila pri lechenii astenicheskogo sindroma i sindroma khronicheskoi ustalosti. Atmosphere. Nervnye Bolezni. 2004;3:28-32. (In Russ.).
Vorob’eva OV. Mnogogrannost’ fenomena astenii. Russkii Meditsinskii Zhurnal. 2012;20(5):248. (In Russ.).
Lebedev MA, Palatov SYu, Kovrov GV, et al. Asthenia: symptom, syndrome, disease. Effective pharmacotherapy. Neurology and Psychiatry. 2014;1:30-38. (In Russ.).
The State Reference Register of medicines. Fonturacetam. (In Russ.). Available by reference: https://grls.rosminzdrav.ru/grls.aspx?s=%D1%84%D0%BE%D0%BD%D1%82%D1%83%D1%80%D0%B0%D1%86%D0%B5%D1%82%D0%B0%D0%BC&m=mnn
Bekuzarova MR, Kumakhov AA. Clinical and laboratory evaluation of the effectiveness of the nootropic drug Actitropil (fonturacetam) in the treatment of asthenic syndrome. Consilium Medicum. 2023;25(11):728-735. (In Russ.). https://doi.org/10.26442/20751753.2023.11.202576
Devlikamova FI. Effektivnost’ i bezopasnost’ preparata Aktitropil u patsientov s astenicheskim sindromom: rezul’taty nablyudatel’noi klinicheskoi programmy. Nervnye Bolezni. 2022;4:36-46. (In Russ.). https://doi.org/10.24412/2226-0757-2022-12933
Vizilo TL. Efficacy and safety of the Actitropil in the treatment of reactive asthenia in young patients. Farmateka. 2023;30(9-10):148-155. (In Russ.). https://doi.org/10.18565/pharmateca.2023.9-10.159-166
Andreyev VV. Experience of using Actitropil in chronic cerebral ischemia: clinical follow-up results. RMZh. Medical Inquiry. 2023;7(10):620-624. (In Russ.). https://doi.org/10.32364/2587-6821-2023-7-10-2
Fedin AI, Amcheslavskaya EV, Krasnoperov EN, Belopasova AV. Primenenie Fenotropila u bol’nykh s khronicheskoi ishemiei mozga i umerennymi kognitivnymi narusheniyami. Rezul’taty randomizirovannogo dvoinogo slepogo platsebokontroliruemogo issledovaniya. Nervnye Bolezni. 2010;3:22-30. (In Russ.).
Yur’eva LN, Dukel’skii AA, Shusterman TI, et al. Otsenka effektivnosti deistviya preparata fenilpiratsetam (Entrop) pri lechenii patsientov s asteniei organicheskogo i nevroticheskogo geneza. Psikhiatriya, Psikhoterapiya i Klinicheskaya Psikhologiya. 2019;10(1):135-147. (In Russ.).
Medvedev VE, Frolova VI, Epifanov AV. New possibilities of pharmacotherapy in cardiovascular patients with mental disorders. SS. Korsakov Journal of Neurology and Psychiatry. 2014;114(9):30-37. (In Russ.).
Nazarov VV, Kolchev AI, Kalinskii PP. Klinicheskie osobennosti astenicheskogo sindroma u lits molodogo vozrasta perenesshikh ishemicheskii insul’t. Rossiiskii Biomeditsinskii Zhurnal. 2008;9:323-331. (In Russ.).
Mokina TV, Antipenko EA, Gustov AV. Effektivnost’ Fenotropila pri lechenii astenicheskogo sindroma u bol’nykh distsirkulyatornoi entsefalopatiei. Lechebnoe Delo. 2010;4:68-72. (In Russ.).
Zhukova NG, Masenko AYa, Kuznetsova KS, et al. Neurometabolic Therapy for Parkinson’s Disease. Lechaschi Vrach. 2023;6(26):62-68. (In Russ.). https://doi.org/10.51793/OS.2023.26.6.009
Zvejniece L, Svalbe B, Veinberg G, et al. Investigation into stereoselective pharmacological activity of phenotropil. Basic Clin Pharmacol Toxicol. 2011;109(5):407-412. https://doi.org/10.1111/j.1742-7843.2011.00742.x
Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70(3):287-312. https://doi.org/10.2165/11319230-000000000-00000
Zvejniece L, Svalbe B, Vavers E, et al. S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity. Pharmacol Biochem Behav. 2017;160:21-29. https://doi.org/10.1016/j.pbb.2017.07.009
Kovalev GI, Akhapkina VI, Abaimov DA, Firstova YuYu. Fenotropil kak retseptornyi modulyator sinapticheskoi neiroperedachi. Atmosfera. Nervnye Bolezni. 2007;4:22-26. (In Russ.).

Close metadata